Employees: 03 (2023.0)Legal category: 5785Size: PMECreation date: 2013-03-20 (13 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: LABERGEMENT-SAINTE-MARIE (25160), Doubs
PHARMACIE CANAL-DREYFUS : revenue, balance sheet and financial ratios
PHARMACIE CANAL-DREYFUS is a French company
founded 13 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in LABERGEMENT-SAINTE-MARIE (25160),
this company of category PME
shows in 2024 a revenue of 2.3 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE CANAL-DREYFUS (SIREN 792085482)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
N/C
2 326 381 €
N/C
2 143 682 €
1 988 538 €
1 860 288 €
2 009 914 €
1 945 605 €
1 772 076 €
1 714 931 €
Net income
87 800 €
88 795 €
125 645 €
269 358 €
163 829 €
148 802 €
154 397 €
167 681 €
134 683 €
156 936 €
EBITDA
N/C
142 505 €
N/C
357 538 €
205 314 €
182 067 €
236 436 €
238 566 €
191 750 €
223 173 €
Net margin
N/C
3.8%
N/C
12.6%
8.2%
8.0%
7.7%
8.6%
7.6%
9.2%
Revenue and income statement
In 2025, PHARMACIE CANAL-DREYFUS generates positive net income of 88 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2025: 157 k€ -> 88 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
87 800 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 30%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 68%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
29.604%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
67.615%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
581.587
658.159
327.248
214.677
158.887
99.336
21.511
52.223
37.389
29.604
Financial autonomy
13.046
11.601
20.858
28.246
35.79
46.807
76.19
56.522
61.316
67.615
Repayment capacity
10.357
11.912
8.599
8.864
9.123
5.258
1.974
None
5.312
None
Cash flow / Revenue
8.02%
6.56%
7.635%
6.564%
6.493%
8.137%
11.817%
None%
3.747%
None%
Sector positioning
Debt ratio
29.62025
2023
2024
2025
Q1: 13.71
Med: 49.76
Q3: 129.07
Good-6 pts over 3 years
In 2025, the debt ratio of PHARMACIE CANAL-DREYFUS (29.60) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
67.61%2025
2023
2024
2025
Q1: 33.42%
Med: 53.71%
Q3: 72.08%
Good+9 pts over 3 years
In 2025, the financial autonomy of PHARMACIE CANAL-DREYFUS (67.6%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Repayment capacity
5.31 years2024
2024
Q1: 0.52 years
Med: 3.19 years
Q3: 7.6 years
Average
In 2024, the repayment capacity of PHARMACIE CANAL-DREYFUS (5.31) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 137.74. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
159.907
119.822
164.117
185.815
291.487
255.815
706.205
137.125
120.862
137.74
Interest coverage
14.314
15.07
10.463
9.308
10.59
7.553
1.767
None
19.175
None
Sector positioning
Liquidity ratio
137.742025
2023
2024
2025
Q1: 131.03
Med: 182.29
Q3: 258.7
Average
In 2025, the liquidity ratio of PHARMACIE CANAL-DREYFUS (137.74) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Interest coverage
19.18x2024
2024
Q1: 0.0x
Med: 2.35x
Q3: 7.73x
Excellent
In 2024, the interest coverage of PHARMACIE CANAL-DREYFUS (19.2x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE CANAL-DREYFUS
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating WCR
207 678 €
194 999 €
216 254 €
248 506 €
211 254 €
157 234 €
1 282 136 €
0 €
184 040 €
0 €
Inventory turnover (days)
35
32
29
30
39
31
31
0
35
0
Customer payment term (days)
6
5
6
6
6
6
8
0
5
0
Supplier payment term (days)
35
39
33
35
21
14
32
0
44
0
Positioning of PHARMACIE CANAL-DREYFUS in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE CANAL-DREYFUS is estimated at
1 394 713 €
(range 946 459€ - 2 188 497€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
946k€1394k€2188k€
1 394 713 €Range: 946 459€ - 2 188 497€
NAF 5 année 2025
Valuation method used
Net Income Multiple
87 800 €
×
15.9x
=1 394 713 €
Range: 946 459€ - 2 188 497€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE CANAL-DREYFUS with other companies in the same sector:
Frequently asked questions about PHARMACIE CANAL-DREYFUS
What is the revenue of PHARMACIE CANAL-DREYFUS ?
The revenue of PHARMACIE CANAL-DREYFUS in 2024 is 2.3 M€.
Is PHARMACIE CANAL-DREYFUS profitable?
Yes, PHARMACIE CANAL-DREYFUS generated a net profit of 88 k€ in 2025.
Where is the headquarters of PHARMACIE CANAL-DREYFUS ?
The headquarters of PHARMACIE CANAL-DREYFUS is located in LABERGEMENT-SAINTE-MARIE (25160), in the department Doubs.
Where to find the tax return of PHARMACIE CANAL-DREYFUS ?
The tax return of PHARMACIE CANAL-DREYFUS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE CANAL-DREYFUS operate?
PHARMACIE CANAL-DREYFUS operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart